Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer
Our results provide preclinical evidence that a subset of colorectal cancers expressing high mesothelin levels can be effectively targeted by MSLN-CAR-based immunotherapy. The potential therapeutic impact of these findings is enhanced by the fact that frequently MSLN-overexpressing CRCs display worse prognosis and resistance to standard care.
Authors
- Dario Sangiolo (ORCID: https://orcid.org/0000-0002-7163-7071)
- Letizia Franco
- Erica Torchiaro (ORCID: https://orcid.org/0000-0002-8984-882X)
- Enzo Médico (ORCID: https://orcid.org/0000-0002-3917-2438)
- Consalvo Petti (ORCID: https://orcid.org/0000-0002-3509-3142)
- Marco Basiricò (ORCID: https://orcid.org/0000-0002-3059-7501)
- Marco Cortese (ORCID: https://orcid.org/0000-0003-0399-9094)
- Federica Invrea (ORCID: https://orcid.org/0000-0002-4912-3744)
- Alice D’Andrea
Institutions
- Candiolo Cancer Institute (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Turin (IT)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1186/s12967-024-05851-y
- Citations
- 8
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 1.92
Funders
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro